| Literature DB >> 26604750 |
Palanivel Ganesan1, Hyun-Myung Ko2, In-Su Kim2, Dong-Kug Choi1.
Abstract
Oxidative stress plays a very critical role in neurodegenerative diseases, such as Parkinson's disease (PD), which is the second most common neurodegenerative disease among elderly people worldwide. Increasing evidence has suggested that phytobioactive compounds show enhanced benefits in cell and animal models of PD. Curcumin, resveratrol, ginsenosides, quercetin, and catechin are phyto-derived bioactive compounds with important roles in the prevention and treatment of PD. However, in vivo studies suggest that their concentrations are very low to cross blood-brain barrier thereby it limits bioavailability, stability, and dissolution at target sites in the brain. To overcome these problems, nanophytomedicine with the controlled size of 1-100 nm is used to maximize efficiency in the treatment of PD. Nanosizing of phytobioactive compounds enhances the permeability into the brain with maximized efficiency and stability. Several nanodelivery techniques, including solid lipid nanoparticles, nanostructured lipid carriers, nanoliposomes, and nanoniosomes can be used for controlled delivery of nanobioactive compounds to brain. Nanocompounds, such as ginsenosides (19.9 nm) synthesized using a nanoemulsion technique, showed enhanced bioavailability in the rat brain. Here, we discuss the most recent trends and applications in PD, including 1) the role of phytobioactive compounds in reducing oxidative stress and their bioavailability; 2) the role of nanotechnology in reducing oxidative stress during PD; 3) nanodelivery systems; and 4) various nanophytobioactive compounds and their role in PD.Entities:
Keywords: Parkinson’s disease; nanocurcumin; nanoresveratrol; nanotechnology delivery systems; phytobioactive compounds
Mesh:
Substances:
Year: 2015 PMID: 26604750 PMCID: PMC4631432 DOI: 10.2147/IJN.S93918
Source DB: PubMed Journal: Int J Nanomedicine ISSN: 1176-9114
Figure 1Nano phytobioactive compounds mechanism of action against Parkinson’s disease pathway.
Notes: Phytobioactive compounds of its unique nanosize successfully cross the blood–brain barrier thereby inhibit the caspases activity and oxidative stress thereby inhibit further activation of glial cells and diseased dopaminergic neurons; also exhibit enhancement of endogenous antioxidant enzyme levels; inhibit the inflammatory cascade. These actions confirmed that phytobioactive compounds will be a successful therapeutic agent for Parkinson’s diseases.
Figure 2Nanotechnology delivery methods for producing nanosized phytobioactive compounds.
Bioavailability of plant-based nanobioactive compounds and their production methods
| Bioactive compounds | Production methods | Particle size (nm) | Experiment models | Bioavailability | References |
|---|---|---|---|---|---|
| Nanocurcumin | Alginate–curcumin nanocomposite | 11.3 | Drosophila model | Increase bioavailability and decrease oxidative stress and apoptosis in Parkinson’s disease | Siddique et al (2013) |
| Solid lipid nanoparticle | 190 | Balb/c mice | Increase concentrations in lungs | Wang et al (2012) | |
| PLGA nanoparticles | 100–200 | HeLa cells | Increase anticancer efficiency | Nair et al (2012) | |
| PLGA nanoparticles | 80–120 | Human neuroblastoma SK-N-SH cells | Decrease neurons against oxidative damage in Alzheimer’s disease | Doggui et al (2012) | |
| PLGA nanoparticles | 158 | Sprague Dawley rats | Increase intravenous bioavailability | Tsai et al (2011) | |
| PLGA nanoparticles | NA | Sprague Dawley rats | Increase neuroprotective effect | Chang et al (2015) | |
| Nanoginsenosides | Nanoliposome | 150 | L929 cells | Enhance the survival rate of H2 O2 -damaged cells | Tsai et al (2012) |
| Ginsenoside compound K-bearing glycol chitosan conjugate nanoparticles | 255 and 296 | Cancer cell lines | Exhibited higher cytotoxicity to HT29, HepG2, and HT22 cancer cells | Mathiyalagan et al (2014) | |
| Nanoresveratrol | Nanocapsule | 241 | Male Wistar rats | Enhanced bioavailability in Alzheimer’s disease | Frozza et al (2010) |
| PCL–PEG polymeric micelles | 100 | PC12 cells | Enhanced bioavailability in Alzheimer’s disease | Lu et al (2009) | |
| Eudragit E100 | 73.8 | Male Wistar rats | Decrease oxidative stress and prevent chronic liver disease | Lee et al (2012) | |
| PEG–PLA–resveratrol conjugates | 150 | Rat C6 and Human U87 glioma cells | Increase antitumor activity | Guo et al (2013) | |
| Resveratrol-loaded PEG–PLA polymeric NPs | 120–233 | Cultured CT26 colon cancer cells in vitro and in CT26 tumor-bearing mice in vivo | Higher antitumor activity | Jung et al (2015) | |
| Nanocatechin | Nanoencapsulation | 432–440 | Swiss outbred mice | Increase bioavailability | Dube et al (2010) |
| Tea polyphenol-loaded chitosan nanoparticles | 400–452 | HepG2 cells | Increase antitumor | Liang et al (2014) | |
| Nanoliposome | 71.7 | In vitro | Increase bioavailability | Zou et al (2014) | |
| Epigallocatechin-3-gallate gold nanoparticle | 64.7 | B16F10 murine melanoma cells | Improved anticancer efficacy | Chen et al (2014) | |
| Epigallocatechin-3-gallate-loaded nanoparticles prepared from chitosan and polyaspartic acid | 102 | Oral administration to rabbits | Decrease atherosclerosis | Hong et al (2014) | |
| Nanoquercetin | Solid lipid nanoparticles | 200 | Male Wistar rats | Increase brain antioxidant capacity | Dhawan et al (2011) |
| Solid lipid nanoparticles | 155.3 | Male Wistar rats | Increase sustained release | Li et al (2009) | |
| Nanosuspension | 430 | In vitro | Higher antioxidant activity | Karadag et al (2014) | |
| Nanoliposomes | 62.3–191.5 | C6 glioma cells | Anticancer activity | Wang et al (2012) | |
| Nanolycopene | Nanostructured lipid carrier | 150–160 | In vitro | Higher antioxidant activity | Okonogi et al (2015) |
| Nanoemulsions | 100–200 | In vitro | Higher bioavailability | Ha et al (2015) |
Abbreviations: NA, not available; NP, nanoparticle; PCL, poly-caprolactone; PEG, polyethylene glycol; PLGA, polylactic-co-glycolic acid.